RYTM Q4 2025 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57M+36.9% YoY

Gross Profit

$52M91.6% margin

Operating Income

-$47M-82.2% margin

Net Income

-$48M-83.0% margin

EPS (Diluted)

$-0.73

QoQ Revenue Growth

+11.6%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$26M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$481M

Total Liabilities

$342M

Stockholders' Equity

$139M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$42M	+36.9%
Gross Profit	$52M	$38M	+37.9%
Operating Income	-$47M	-$41M	-14.1%
Net Income	-$48M	-$43M	-9.7%

Revenue Segments

Product

$57M85%

License

$10M15%

Geographic Segments

Non-US

$18M100%